State University of New York at Buffalo
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, State University of New York at Buffalo sits in the top decile of US sponsors by registered trial count (#135 of 15,742 sponsors by registered trial count).
State University of New York at Buffalo: 243 sponsored US clinical trials, 52 recruiting.
State University of New York at Buffalo sponsors 243 registered US clinical trials on ClinicalTrials.gov, 52 of them currently recruiting, and 156 completed. 19 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 4 trials.
Top-decile sponsor footprint
State University of New York at Buffalo ranks in the top decile of sponsors by registered trial count (#135 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
156 of 172 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
243 total, page 2 of 5
Blood Collection Biorepository for Liver Disease Research
NCT03025074
Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders
NCT00682513
Interventions to Decrease Health Information Avoidance
NCT06972667
Community Recreation to Enhance Function in Aging
NCT07104435
Investigating Metabolic and Psychological Adaptations in a Clinical Trial
NCT06800794
Repurposing Lithium for Parkinson's Disease: a RCT
NCT06339034
Family-Based Treatment for Type 1 Diabetes
NCT05756361
Conditional Cash Transfer Intervention to Improve T2DM
NCT05559892
Lowering Food Insecurity and Improving Diabetes With Financial Incentives
NCT05352022
Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication
NCT05154773
Surveying Patient's Interest in Robotic Rehabilitation Device
NCT05417802
Bictegravir in the Elderly Living With HIV (BICEP)
NCT05064020
Lowering the Impact of Food Insecurity in African American Adults With Type 2 Diabetes Mellitus (LIFT-DM)
NCT04181424
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1
NCT04203173
Triple Therapy in T1DM
NCT03899402
Prediction of ARrhythmic Events With Positron Emission Tomography II
NCT03493516
Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation
NCT07072767
Examining Migration, Social Bonds, Transnationalism, and HIV Prevention Pathways Among African Immigrants.
NCT07565584
AI-Enhanced App-based Intervention for Adolescent E-cigarette Cessation
NCT06965296
The Effect of Osteoporotic Medications on Vertebral Bone Quality Score
NCT07587775
Robotic Rehabilitation for Stroke Survivors
NCT05417828
Toddler Tastes Study
NCT06877468
Effects of a Lower Back Wrap Device on Lower Back Pain, Physical Function, and Quality of Life
NCT06749912
Pharmacist-Led SDoH Screening Intervention During Transitions of Care in an Acute Care Setting
NCT06802393
Sevoflurane Concentrations in Children
NCT06510803
Anomia Treatment Predictors
NCT06619756
Feasibility of Aerobic Exercise for Recovery From Work-related Concussion
NCT06263179
The Effects of an Acute High-intensity Exercise on Heart and Brain Function in People With Spinal Cord Injury
NCT06274658
Survivor Mom Companion Comparison Study
NCT06318663
Promoting Food Acceptance Through Positive Parenting: the Play and Grow Study
NCT06074926
Virtual Reality at End-of-life
NCT06149429
Repurposing Lithium for Parkinson's Disease
NCT06099886
Lithium Long COVID Dose-finding Study
NCT06108297
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
NCT05974839
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
NCT05974852
Social Workers Addressing Firearm Risk
NCT05784662
The Role of Mechanical Diagnosis and Therapy in the Management of Concussion
NCT05859815
Dehydration Cognition
NCT05916183
The Family Grocery Pilot: Optimal Defaults in Online Grocery Shopping Among Families
NCT05899634
Dual-task Training for Function in MCI
NCT04059705
Effect of Lithium Therapy on Long COVID Symptoms
NCT05618587
Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers
NCT05472935
The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury
NCT05542238
Semaglutide Use in Elderly Obese Patients
NCT05302596
Weight Management Program for Patients With First Episode Psychosis
NCT05207982
Piloting Mindfulness Meditation Program for Underserved Racial Minority Adults With Pulmonary Hypertension
NCT05387889
The Baby Care Study
NCT05322174
Short- and Long-term Health Consequences of Workers During Consecutive Days of Heat Stress
NCT05302674
Salivary Biomarkers for Concussion Recovery
NCT05379920
Alterations in Gait, Strength, and Power After Ruck Marching
NCT05309603
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 15 |
| Phase 3 | 7 |
| Phase 4 | 12 |
What is open in the State University of New York at Buffalo pipeline
52 recruiting of 243 indexed (21% open); 156 completed (64%).
Phase mix: 19 late (III/IV) vs 26 early (I/II) (balanced across stages).
Top condition: Multiple Sclerosis (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
State University of New York at Buffalo: open-pipeline peers nationwide
Peers matched on 243 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
State University of New York at Buffalo sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 243 trials (± recruiting share)
- Shire · 245 trials · 0% recruiting
- University of Cincinnati · 245 trials · 14% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
- Incyte Corporation · 239 trials · 15% recruiting
Sponsors near 21% open enrollment (± trial volume)
- Axsome Therapeutics · 21% recruiting · 28 trials
- GOG Foundation · 21% recruiting · 14 trials
- Kettering Health Network · 21% recruiting · 14 trials
- LifeBridge Health · 21% recruiting · 14 trials
Related
What to do with this State University of New York at Buffalo page
243 registered trials is a research-attention snapshot, not an endorsement of State University of New York at Buffalo or any single study.
- 52 of State University of New York at Buffalo's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis is the condition State University of New York at Buffalo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
State University of New York at Buffalo pipeline card: 243 registered trials from official public datasets.Report a data error.